Table 2. Clinical characteristics, management and outcomes of patients with CMV reactivation.

|  |  |
| --- | --- |
| Modality | Number (%) |
| CMV reactivationYesNo  | 37 (17.6%)173 (82.4%) |
| Time to reactivation, daysMedian (range) | 31 (21-54) |
| Anti-CMV therapyGanciclovirValganciclovirFoscarnet | 26 (70.3%)9 (24.3%)2 (5.4%) |
| Treatment-related complicationsPancytopenia NeutropeniaThrombocytopeniaRenal impairmentHypomagnesaemiaHypocalcemiaOther complications | 3 (8.1%)5 (13.5%)4 (10.8%)2 (5.4%)5 (13.5%)1 (2.7%)3 (8.1%) |
| Duration of anti-CMV therapy, days Induction therapy, median (range)Maintenance therapy, median (range) | 8 (4-15)10 (6-16) |
| Development of CMV diseaseYes No  | 0 (0%)37 (100%) |
| MortalityOverall Day 100 | 11 (29.7%)0 |